Evidence map›Paper›PMID 20576128›Full record

ArticleBMC cancer2010

Bicyclic triterpenoid Iripallidal induces apoptosis and inhibits Akt/mTOR pathway in glioma cells.

Nitin Koul, Vivek Sharma, Deobrat Dixit, Sadashib Ghosh, Ellora Sen

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 27 citations in OpenAlex.

  1. Dual Modulatory Effects of Phytochemicals fromMolecules (Basel, Switzerland) · 2025
    Article
  2. Genome assembly of the bearded iris,GigaByte (Hong Kong, China) · 2023
    Article
  3. Article
  4. OncoTargets and therapy · 2021
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nitin KoulNational Brain Research Centre, Manesar, Haryana, India. ellora@nbrc.ac.in
Vivek Sharma
Deobrat Dixit
Sadashib Ghosh
Ellora Sen
National Brain Research Centre · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe highly resistant nature of glioblastoma multiforme (GBM) to chemotherapy prompted us to evaluate the efficacy of bicyclic triterpenoid Iripallidal against GBM in vitro.

methodsThe effect of Iripallidal on proliferation and apoptosis in glioma cell lines was evaluated by MTS, colony formation and caspase-3 activity. The effect of iripallidal to regulate (i) Akt/mTOR and STAT3 signaling (ii) molecules associated with cell cycle and DNA damage was evaluated by Western blot analysis. The effect of Iripallidal on telomerase activity was also determined.

resultsIripallidal (i) induced apoptosis, (ii) inhibited Akt/mTOR and STAT3 signaling, (iii) altered molecules associated with cell cycle and DNA damage, (iv) inhibited telomerase activity and colony forming efficiency of glioma cells. In addition, Iripallidal displayed anti-proliferative activity against non-glioma cancer cell lines of diverse origin.

conclusionThe ability of Iripallidal to serve as a dual-inhibitor of Akt/mTOR and STAT3 signaling warrants further investigation into its role as a therapeutic strategy against GBM.

Indexed as

AcroleinApoptosisBlotting, WesternBrain NeoplasmsCaspase 3Cell CycleCell Line, TumorCell ProliferationCyclohexanolsGlioblastomaHumansProto-Oncogene Proteins c-aktSignal TransductionTelomeraseTOR Serine-Threonine Kinases26-hydroxy-22-methylcycloirid-16-enalAcroleinCaspase 3CyclohexanolsProto-Oncogene Proteins c-aktTelomeraseTOR Serine-Threonine Kinases

Identifiers

PMID20576128
PMCPMC2916920
OpenAlexW2125242602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.